aspartic acid has been researched along with Atherosclerotic Parkinsonism in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anheim, M; Bousset, L; Brice, A; Dürr, A; Honoré, A; Lesage, S; Letournel, F; Madiona, K; Melki, R; Pieri, L; Rozas, N; Verny, C | 1 |
| Fang, F; Fang, K; Hou, Z; Lei, H; Lin, X; Liu, M; Liu, S; Meng, H; Sun, B; Zhang, Z | 1 |
| Abarca, J; Bustos, G; Bustos, V; Campusano, J; Moya, C; Noriega, V; Riquelme, E | 1 |
| Goursaud, S; Hermans, E; Massie, A; Meshul, CK; Michotte, Y; Schallier, A; Vermoesen, K | 1 |
| Bisdas, S; Engeholm, M; Gasser, T; Krüger, R; Schittenhelm, J; Wächter, T | 1 |
| Aschner, M; Criswell, SR; Dydak, U; Guilarte, TR; Racette, BA; Zheng, W | 1 |
| Loopuijt, LD | 1 |
| Fukuda, R; Fukui, T; Iwanami, A; Kasai, K; Kato, N; Kato, T; Yamasue, H | 1 |
| Prockop, LD | 1 |
| Antonini, A; Bresolin, N; Canesi, M; Farabola, M; Ghione, I; Pezzoli, G; Rango, M; Righini, A | 1 |
| Beal, MF; Brouillet, E; Chen, YC; Jenkins, BG; Kirschner, P; Rosen, BR; Schulz, JB; Storey, E | 1 |
| De Mari, M; Federico, F; Giannini, P; Iliceto, G; Lamberti, P; Lucivero, V; Mezzapesa, DM; Simone, IL; Tarantino, A | 1 |
| Chang, LJ; Hornykiewicz, O; Kish, SJ; Mirchandani, L; Shannak, K | 1 |
| Boyce, S; Crossman, AR; Luquin, MR; Peggs, D; Sambrook, MA | 1 |
14 other study(ies) available for aspartic acid and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome.
Topics: Adult; Aged; Aged, 80 and over; alpha-Synuclein; Amyloid; Aspartic Acid; Blepharospasm; Caspase 3; DNA Mutational Analysis; Dose-Response Relationship, Drug; Family Health; Female; France; Globus Pallidus; Glycine; Humans; Male; Middle Aged; Mutation, Missense; Neuroblastoma; Neurofilament Proteins; Parkinson Disease, Secondary | 2013 |
Parkinson's disease: in vivo metabolic changes in the frontal and parietal cortices in 6-OHDA treated rats during different periods.
Topics: Animals; Aspartic Acid; Choline; Corpus Striatum; Creatine; Disease Models, Animal; Frontal Lobe; Functional Laterality; Functional Neuroimaging; Glutamates; Glutamic Acid; Glutamine; Magnetic Resonance Spectroscopy; Male; Motor Activity; Oxidopamine; Parietal Lobe; Parkinson Disease, Secondary; Rats; Substantia Nigra; Time Factors | 2014 |
NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
Topics: Analysis of Variance; Animals; Aspartic Acid; Brain-Derived Neurotrophic Factor; Cell Count; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Functional Laterality; Glutamic Acid; Male; Microdialysis; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation | 2009 |
Time-dependent changes in GLT-1 functioning in striatum of hemi-Parkinson rats.
Topics: Animals; Aspartic Acid; Blotting, Western; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Immunohistochemistry; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Piperazines; Rats; Synaptosomes; Time Factors | 2010 |
Slowly progressive Parkinson syndrome due to thalamic butterfly astrocytoma.
Topics: Aged; Aspartic Acid; Astrocytoma; Brain Neoplasms; Brain Stem; Choline; Glial Fibrillary Acidic Protein; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Parkinson Disease, Secondary; Thalamus | 2011 |
Pathophysiology of manganese-associated neurotoxicity.
Topics: Air Pollutants, Occupational; Animals; Aspartic Acid; Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Imaging; Manganese; Manganese Poisoning; Models, Animal; Occupational Diseases; Occupational Exposure; Occupational Health; Parkinson Disease, Secondary; Phenotype; Positron-Emission Tomography; Risk Assessment; Risk Factors | 2012 |
Local application of L- threo-hydroxyaspartate and malonate in rats in vivo induces rigidity and damages neurons of the substantia nigra, pars compacta.
Topics: Animals; Aspartic Acid; Behavior, Animal; Brain Mapping; Catalepsy; Cell Count; Coloring Agents; Locomotion; Male; Malonates; Muscle Rigidity; Nerve Degeneration; Neurons; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2002 |
Drug-induced parkinsonism in relation to choline-containing compounds measured by 1H-MR spectroscopy in putamen of chronically medicated patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Basal Ganglia Diseases; Choline; Chronic Disease; Creatine; Dominance, Cerebral; Energy Metabolism; Female; Glutamic Acid; Glutamine; Humans; Inositol; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Phosphocreatine; Putamen; Reference Values; Schizophrenia; Schizophrenic Psychology | 2003 |
Carbon monoxide brain toxicity: clinical, magnetic resonance imaging, magnetic resonance spectroscopy, and neuropsychological effects in 9 people.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Basal Ganglia; Brain; Carbon Monoxide Poisoning; Child; Chronic Disease; Cognition; Coma; Comprehension; Female; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Mental Processes; Neuropsychological Tests; Parkinson Disease, Secondary; Thinking; Unconsciousness | 2005 |
Parkinson's disease, chronic hydrocarbon exposure and striatal neuronal damage: a 1-H MRS study.
Topics: Aged; Aspartic Acid; Choline; Creatine; Humans; Hydrocarbons; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neostriatum; Neurons; Occupational Exposure; Parkinson Disease, Secondary; Solvents | 2006 |
Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging.
Topics: Aging; Animals; Aspartic Acid; Electron Transport Complex II; Energy Metabolism; Huntington Disease; Lactates; Lactic Acid; Magnetic Resonance Spectroscopy; Male; Multienzyme Complexes; Nerve Degeneration; Neurochemistry; Neurotoxins; Oxidoreductases; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Succinate Dehydrogenase | 1996 |
Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.
Topics: Aged; Antiparkinson Agents; Aspartic Acid; Atrophy; Cerebral Cortex; Choline; Corpus Striatum; Creatinine; Female; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Spectroscopy; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Phosphocreatine; Protons; Putamen; Supranuclear Palsy, Progressive | 1997 |
Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers.
Topics: Aged; Aspartic Acid; Basal Ganglia Diseases; Brain; Bulbar Palsy, Progressive; Choline O-Acetyltransferase; Dementia; Dopamine; Female; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Neurons; Neurotransmitter Agents; Norepinephrine; Parkinson Disease, Secondary; Serotonin | 1985 |
Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey.
Topics: Animals; Aspartic Acid; Dibenzocycloheptenes; Dizocilpine Maleate; Injections, Intramuscular; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; N-Methylaspartate; Parkinson Disease, Secondary | 1989 |